Grant of Award

Oxford Biomedica granted 94,156 nil-cost share options to its COO under the 2026 LTIP.

What the company is saying

Oxford Biomedica plc (LSE:OXB) has granted 94,156 nil-cost share options to Chief Operating Officer Eric Schmidhaeuser under its 2024 Long Term Incentive Plan, with the grant dated 30 September 2026. The company frames this as a routine regulatory disclosure, specifying that the LTIP for 2026 is weighted 60% on revenue and 40% on Operating EBITDA margin, with targets assessed on a constant currency basis. No consideration was paid for the grant, and the options relate to ordinary shares of 50 pence each. The announcement is positioned as an initial notification for a person discharging managerial responsibilities, fulfilling legal and transparency requirements. The company provides all required transaction details, including ISIN (GB00BDFBVT43), LEI (213800S1GVQNXQ15K851), and confirms the transaction occurred outside the trading venue in GBP. There is no promotional language or forward-looking commentary beyond the basic performance metric structure.

What the data suggests

The facts confirm that Eric Schmidhaeuser, as Chief Operating Officer, received 94,156 nil-cost share options on 30 September 2026 under the 2024 LTIP. The performance criteria for vesting are explicitly weighted: 60% revenue and 40% Operating EBITDA margin, with both assessed on a constant currency basis. The grant price is nil, and the options pertain to ordinary shares with a nominal value of 50 pence each. No cash or other consideration was exchanged for the award. The announcement provides all regulatory identifiers and required transaction details but does not disclose the actual revenue or EBITDA margin targets, nor any current or historical financial results. The disclosure is complete for its regulatory purpose but does not provide broader insight into company performance or financial trajectory.

Analysis

This announcement is a routine regulatory disclosure regarding the grant of nil-cost share options to a senior executive under the company's Long Term Incentive Plan. The language is factual and procedural, with no promotional or exaggerated claims about company performance or future prospects. The only forward-looking element is the reference to future performance metrics (revenue and Operating EBITDA margin) that will determine the vesting of the LTIP, but no targets or projections are stated. There is no discussion of capital outlay, operational milestones, or financial impact, and no attempt to frame the grant as a value-creating event for shareholders. The data fully supports the claims made, which are limited to the mechanics of the LTIP grant.

Risk flags

• ●The award's value to the recipient and potential dilution to shareholders depend entirely on Oxford Biomedica meeting undisclosed 2026 revenue and EBITDA margin targets, introducing uncertainty about eventual vesting and impact.
• ●The absence of disclosed target ranges for the performance metrics means investors cannot independently assess the difficulty or achievability of the LTIP hurdles, limiting transparency on executive incentive alignment.
• ●As with all equity-based compensation, there is a risk of shareholder dilution if the options vest, though the scale (94,156 shares) is modest relative to total share capital.

Bottom line

This is a routine regulatory disclosure of a nil-cost share option grant to Oxford Biomedica's Chief Operating Officer, tied to 2026 performance on revenue and EBITDA margin. The announcement is factual, with no promotional claims and all required transaction details provided. Investors cannot assess the likelihood of vesting or the stringency of targets, as the actual performance thresholds remain undisclosed. The scale of the grant is not large in the context of a FTSE250 company, and no immediate financial or operational impact results from this notice. The most relevant takeaway is that executive incentives remain closely tied to top-line and profitability metrics, but the real impact will only be clear when actual 2026 results and LTIP performance are reported.

Announcement summary

(LSE:OXB) Oxford Biomedica plc announced that on 30 September 2026, nil-cost share options over ordinary shares of 50 pence each were granted under the Company’s 2024 Long Term Incentive Plan (LTIP). The grant was made to Eric Schmidhaeuser, Chief Operating Officer, for a total of 94,156 share options. The 2026 LTIP metrics are weighted 60% on revenue and 40% on Operating EBITDA margin, with target ranges for each assessed on a constant currency basis as set out in the Company’s Directors’ Remuneration Report for 2025. The ISIN for the ordinary shares is GB00BDFBVT43. The transaction was conducted outside the trading venue and the currency is GBP – British Pound. No consideration was paid for the grant of the awards. The notification is an initial notification for a person discharging managerial responsibilities (PDMR). The legal entity identifier (LEI) for Oxford Biomedica plc is 213800S1GVQNXQ15K851. The nature of the transaction is the grant of LTIP awards over ordinary shares under the Company's Long Term Incentive Plan. The aggregated volume of LTIP awards granted is 94,156 shares in total at a nil price. The grant is in respect of the 2026 performance period. The Company is headquartered in Oxford, UK, and has development and manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Natalie Walter is the Chief Legal Officer and Group Company Secretary. The announcement was made on 02 October 2026.

Disagree with this article?